References
- 1. Baird K, Pavletic SZ. Chronic graft versus host disease. Curr Opin Hematol 2006;13:426-35.
- 2. Hausermann P, Walter RB, Halter J, Biedermann BC, Tichelli A, Itin P, et al. Cutaneous graft-versus-host disease: a guide for the dermatologist. Dermatology 2008;216:287-304.
- 3. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004;104:3501-6.
- 4. Arora M. Therapy of chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21:271-9.
- 5. Stander H, Schiller M, Schwarz T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol 2002;46:799-800.
- 6. Kroft EB, Berkhof NJ, van de Kerkhof PC, Gerritsen RM, de Jong EM. Ultraviolet A phototherapy for sclerotic skin diseases: a systemic review. J Am Acad Dermatol 2008; 59:1017-30.
- 7. Mutzhas MF, Holzle E, Hofmann C, Plewig G. A newapparatus with high radiation energy between 320 and 460 nm: physical description and dermatological applications. J Invest Dermatol 1981;76:42-7.
- 8. Rombold S, Lobish K, Katzer K, Grazziotin TC, Ring J, Eberlein B. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008;24:19-23.
- 9. Grundmann-Kollmann M, Behrens S, Gruss C, Gottlober P, Peter RU, Kerscher M. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000;42:134-6.
- 10. Calzavara PP, Porta F, Izzi T, Venturini M, Capezzera R, Zane C, et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica 2003;88:1169-75.
- 11.Wetzig T, Sticherling M, Simon JC, Hegenbart U, Niederwieser D, Al-Ali HK. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host diease of the skin. Bone Marrow Transplant 2005;35:515-9.
- 12. Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatology 2004;4:11.
- 13. Krutmann J, Czech W, Djepgen T, Niedner R, Kapp A, Schopf E. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992;26:225-30.
- 14. Fleischmajer R, Damiano V, Nedwich A. Alteration of subcutaneous tissue in systemic scleroderma. Arch Dermatol 1972;105:59-66.
- 15. Scharffetter K, Wlaschek M, Hogg A, Bolsen K, Schothorst A, Goerz G, et al. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991;283:506-11.
- 16. Takeda K, Hatamochi A, Ueki H. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994;103:359-63.
- 17. Sakakibara N, Sugano S, Morita A. Ultrastructural changes induced in cutaneous collagen by ultraviolet-A1 and psoralen plus ultraviolet A therapy in systemic sclerosis. J Dermatol 2008;35:63-9.
- 18. Dawe RS. Ultraviolet A1 phototherapy: topical review. Br J Dermatol 2003;148:626-37.